Yahoo Finance Live anchors discuss stock performance for cruise lines.
Leaving these accounts open could tarnish your golden years.
In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.
Yahoo Finance's Josh Schafer discusses Wall Street analyst calls on Nike after the athletic apparel giant reported some red flags in its earnings results.
In this article, we will look at 5 high-yielding dividend stocks to buy according to journalist investor Jim Cramer. If you want to explore similar stocks, you can also take a look at Jim Cramer is Recommending These 2 High-Yield Dividend Stocks. The Short-Term Camp Vs The Silent Majority Following the Fed’s 75 basis point […]
Yesterday I posed the question, "If Carnival misses on earnings tomorrow, what will that mean for Royal Caribbean and Norwegian Cruise Line Holdings?" Well, guess what? Turns out, Carnival Corporation (NYSE: CCL) (NYSE: CUK) did miss on earnings -- badly -- and as a result, not just Carnival stock but fellow cruise line stocks Royal Caribbean (NYSE: RCL) and Norwegian Cruise Line Holdings (NYSE: NCLH), too, are falling hard.
Shares of Carnival (NYSE: CCL), the world's biggest cruise line operator, were tumbling today after the company badly missed estimates in its third-quarter earnings report. Carnival continued to rebound from the pandemic in the third quarter, but its results fell short of expectations and it reported a significant loss. Revenue jumped nearly 80% sequentially from the second quarter to $4.31 billion, but that still missed analysts' consensus estimate of $5.07 billion.
Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. ET Friday morning. The biotech's stock appears to be getting a boost from both a broad upward trend across the biotechnology space today, as well as from rumors circulating on social media about a possible buyout. Bluebird scored two approvals from the Food and Drug Administration (FDA) earlier this year for its one-and-done gene therapies: Skysona for cerebral adrenoleukodystrophy (CALD) and Zynteglo for transfusion-dependent beta-thalassemia (TDT).
Inflation, interest rates, and recession – these are the bogeymen of investing, and they’ve been watching over our shoulders for the past several months. We all know the story by now, the rate of inflation is running at generational highs, the Federal Reserve is hiking rates in an attempt to push back against high prices, and that’s likely to tip the economy into recession. At a time like this, investors are showing a growing interest in finding strong defensive portfolio moves. It’s a mindset t
Intel Corporation (NASDAQ:INTC) started an accelerated downtrend in August. The company lost 27% of its market value since then, and investors may be concerned about the near future. Looking at analysts forecasts, it seems that there may be some more pain ahead. We break down the fundamentals, future expectations, and see what that means for investors in our analysis.
AT&T is trading lower Thursday and is very close to a major support breakdown. How major do you ask? Let's look at one Point and Figure chart. In the daily Point and Figure chart of T, below, we used close-only price data.
With the S&P 500 index making new lows in 2022, it is crucial investors stay the course and continue adding high-quality businesses to their portfolios -- through dollar-cost averaging, if possible. Shopify (NYSE: SHOP) is currently light on profits yet is vital to the burgeoning U.S. e-commerce industry. Adyen (OTC: ADYE.Y) and InMode (NASDAQ: INMD) offer the beautiful pairing of high sales growth and strong free cash flow (FCF) creation and profitability.
In this article, we shall discuss the 10 best value stocks to buy now. To skip our comprehensive analysis of the global economic outlook in 2022, go directly and see 5 Best Value Stocks to Buy Now. As of September 2022, the global economic outlook is dismal as the threat of an impending recession looms. […]
Billionaire investor Stanley Druckenmiller sees a “hard landing” by the end of 2023 as the Federal Reserve’s aggressive monetary tightening will tip the U.S. economy into recession.
Nvidia (NASDAQ: NVDA) has been a top performer on the stock market over the years, with shares of the graphics card specialist rising more than 3,600% over the past decade. The broader market correction has sent shares of Nvidia packing, with the tech giant losing more than 60% of its value since December 2021. The sell-off has brought Nvidia's market capitalization down to just over $300 billion from more than $800 billion in December last year.
The Dow Jones Industrial Average dropped Friday on hot inflation data. Tesla stock fell ahead of the company's AI Day.
While investing in stocks is a proven way to build wealth in the long term, high-yield dividend stocks that provide you with passive income can make your money grow much faster. The stock market sell-off is one of the best times to hunt for such passive income streams. Right now, stocks from top-performing sectors like oil are offering compelling opportunities to earn passive income for years to come.
Artisan Partners, an investment management company, released its “Artisan International Value Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, its Investor Class fund ARTKX returned -10.47%, Advisor Class fund APDKX posted a return of -10.42%, and Institutional Class fund APHKX returned -10.41%, compared to a […]
Tesla's production forecast, if achieved, would put the EV maker on track to meet Elon Musk's goal for production in the coming quarter and put the automaker close to the scale of German luxury automaker BMW by end 2023. Musk and Tesla have a record of pointing to stretch targets the company has not always met. In April, for instance, Musk had said Tesla could hit 60% growth in deliveries.
Yahoo Finance Live’s Brian Sozzi joins the Live show to discuss a Raymond James analyst’s Outperform rating on Microsoft.